long intergenic non-protein coding RNA 2675Genealiases: []
Q-omics provides the consensus-scored LINC02675 profile across patient tissues and cancer cell-line models. LINC02675 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02675 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LINC02675 RNA expression shows 7,102 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, KIRC, and KIRP as cancer lineages where LINC02675 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02675 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02675 survival associations across molecular data types. LINC02675 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02675 RNA expression–survival associations across cancer types. High LINC02675 expression shows unfavorable associations in COAD, UVM and TGCT, but favorable associations in KIRP, LGG and LUSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02675 RNA expression.
This table summarizes LINC02675 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02675. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02675 shows lower tumor expression in KIRC, KIRP, KICH, LUSC, LUAD and BRCA. The KIRC box plot shows higher LINC02675 RNA expression in normal versus tumor tissue (log2 FC = −2.254, t-test p < 0.001).
This table shows molecular features associated with LINC02675 in patient tissues and cancer cell lines. In patient samples, LINC02675 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
